What are the signs of dermatomyositis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Signs of Dermatomyositis

Dermatomyositis presents with characteristic cutaneous findings combined with symmetric proximal muscle weakness, though skin manifestations may appear alone or precede muscle involvement by months to years. 1

Pathognomonic Cutaneous Signs

The following skin findings are diagnostic of dermatomyositis:

  • Heliotrope rash: Violaceous periorbital edema with erythema 1
  • Gottron papules: Erythematous to violaceous papules over the dorsal metacarpophalangeal and interphalangeal joints 1, 2
  • Gottron sign: Erythematous macules over bony prominences (elbows, knees) 2

Characteristic Cutaneous Manifestations

Additional skin findings strongly associated with dermatomyositis include:

  • Periungual telangiectasias with cuticular overgrowth 1, 2
  • Poikiloderma: Atrophic skin changes with hyperpigmentation, hypopigmentation, and telangiectasias 1
  • Photosensitive erythematous rash involving face, neck, torso, and extensor surfaces of extremities 1
  • V-sign and shawl sign: Erythema over anterior chest/neck and upper back/shoulders 2
  • "Mechanic's hands": Hyperkeratotic, cracked skin on palmar and lateral aspects of fingers 2

Musculoskeletal Signs

The muscle involvement follows a characteristic pattern:

  • Symmetric proximal muscle weakness developing over weeks to months 1
  • Difficulty with tasks requiring proximal strength (climbing stairs, rising from chairs, lifting arms overhead) 1
  • Elevated muscle enzyme levels (creatine kinase, aldolase, AST, ALT, LDH) 1
  • Muscle tenderness may be present but is not universal 1

Extramuscular Manifestations

Systemic involvement significantly impacts morbidity and mortality:

Pulmonary

  • Interstitial lung disease (most common pulmonary manifestation, presenting as nonspecific interstitial pneumonitis) 1, 3
  • Aspiration pneumonia secondary to pharyngeal muscle weakness 1

Gastrointestinal

  • Dysphagia from cricopharyngeal muscle dysfunction (poor prognostic factor) 1, 3
  • Dysphonia 1

Cardiac

  • Asymptomatic arrhythmias (sinus tachycardia) detected on electrocardiography 1
  • Diastolic dysfunction on echocardiography 1
  • Myocarditis (found on autopsy studies, associated with increased mortality) 1, 3

Constitutional

  • Fever, weight loss, and fatigue 3, 2
  • Raynaud phenomenon 1, 2
  • Nonerosive inflammatory polyarthritis 2

Diagnostic Criteria (Bohan and Peter)

A definite diagnosis requires 4 of 5 criteria:

  1. Characteristic skin findings 1
  2. Proximal muscle weakness 1
  3. Elevated muscle enzyme levels 1
  4. Myopathic pattern on EMG (polyphasic motor unit action potentials of short duration and low amplitude, increased insertional activity with fibrillation potentials) 1
  5. Endomysial mononuclear inflammatory infiltrate on muscle biopsy 1

Special Variants

Amyopathic Dermatomyositis

  • Classic rash without muscle weakness 1
  • Normal muscle enzyme levels within 2 years of diagnosis 1
  • Normal EMG findings 1
  • Interstitial lung disease may still occur 1

Hypomyopathic Dermatomyositis

  • Classic rash without clinical muscle weakness 1
  • Evidence of subclinical muscle inflammation (mild CK elevation, EMG abnormalities, MRI changes) 1

Juvenile Dermatomyositis

  • Occurs in patients <18 years of age 1
  • Calcinosis cutis is characteristic (less common in adults) 1, 3
  • Cutaneous vasculitis and ulcerations more frequent than in adults 1
  • Gastrointestinal vasculopathy with potential bowel ischemia/infarction 1
  • Nailfold capillaroscopy useful for predicting disease severity 1

Critical Clinical Pitfalls

Screen all newly diagnosed patients for malignancy, as dermatomyositis carries a 3-8 times increased cancer risk compared to the general population 2. This risk is particularly elevated in elderly patients 3.

Cardiac involvement and dysphagia are poor prognostic factors that significantly increase morbidity and mortality 3. Even asymptomatic cardiac manifestations warrant monitoring, as severe complications may not be clinically apparent initially 1.

Myositis-specific autoantibodies predict extramuscular organ involvement (particularly pulmonary and cardiac systems) and offer prognostic value 1, 3. Testing should be performed at diagnosis to guide monitoring strategies.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical presentation and evaluation of dermatomyositis.

Indian journal of dermatology, 2012

Guideline

Extramuscular Manifestations of Inflammatory Myopathies

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.